Poland's Health Ministry approval a Phase IIa clinical trial of NasVax's Type C hepatitis treatment at the Bydgoszcz military hospital.
NasVax Ltd. (TASE: NSVX) has obtained Polish Ministry of Health approval for a Phase IIa clinical trial of its Type C hepatitis treatment at the Bydgoszcz military hospital. The trial will evaluate the efficacy and safety of the anti-CD3 oral antibody.
Trial will include a group that will receive a placebo. The trial will evaluate various dosages of the treatment on various immunology measurements. In March, NasVax reported successful results of the treatment in a Phase IIa clinical trial trial in Israel on patients with non- Alcoholic Steatohepatitis (NASH) liver disease.
Published by Globes [online], Israel business news - www.globes-online.com - on August 7, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011